Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05571839 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT05571839: Active Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT05571839 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 41 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05571839, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.
Primary Outcome
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG PF-08046049
Study Locations (20)
California
- UCLA Hematology/Oncology - Administrative Office - Los Angeles
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center, Drug Information Center - Los Angeles
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology/ Oncology- Pasadena - Pasadena
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCSF Medical Center, Investigational Pharmacy - San Francisco
- UCLA Hematology/Oncology - Santa Barbara - Santa Barbara
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only) - Santa Monica
- UCLA Hematology - Oncology Clinic - Westlake Village - Westlake Village
Colorado
- Quest Diagnostics Incorporated - Denver - Denver
- Presbyterian/St. Lukes Medical Center - Denver
Illinois
- Northwestern Medical Group - Chicago
- Northwestern Memorial Hospital - Chicago
Massachusetts
- BWH - Boston
- Dana-Farber Cancer Institute (DFCI) - Boston
New York
- Ambulatory Care Center at NYU Langone Medical Center - New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
New Jersey
- Laboratory Corporation of America - Raritan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2026-06-06 |
| Phase | Phase 1 |
What the registry record for NCT05571839 still lists
NCT05571839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-08046049 is the first listed.
NCT05571839 names 20 study sites across 6 states, led by California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05571839 about?
NCT05571839 is a clinical study titled "A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors". This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the...
What is the current status of trial NCT05571839?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-01-03. Estimated completion is 2026-06-06.
What conditions does trial NCT05571839 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Neoplasms, Mesothelioma, Pancreatic Neoplasms, Cutaneous Melanoma.
What interventions are being tested in trial NCT05571839?
The interventions under investigation include: PF-08046049 (DRUG).
Who is sponsoring clinical trial NCT05571839?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05571839 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05571839's enrollment target sits among peer trials
41 356th of 454 higher than 96 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI